Furthermore, in a phase-II clinical trial involving early-stage NSCLC patients, the combination of SBRT (three fractions of 8 Gy) and durvalumab (anti-PD-1) promoted a notable increase in pathological response rate compared to patients treated with durvalumab monotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.